These innovative agents represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose levels. https://elainewpqz650877.blogs-service.com/70116274/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide